Search

Displaying results 1041 - 1050 of 8412 in total
  1. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. It is intravenously administered so that the antivenin binds to and neutra...

  2. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity

    Mixtures: Multiple Vitamins (Pediatric) Single Dose Vial, Vitamin D2 and K1
  3. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  4. Drug

    Ornidazole

    go.drugbank.com/drugs/DB13026
    Investigational

    Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

    Products: TIBERAL ROCHE DE 500 MG
  5. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  6. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  7. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

    Mixtures: Sag-M, Sag-mannitol Solution
  8. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  9. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.